Sysmex Corporation
Stock Price Chart
2026/06/15 UpdatedPrice Trend
2026/06/15 UpdatedPrice & Trading Details
2026/06/15 UpdatedPRICE
TRADING
Analyst Recommendations 15 analysts
Updated 2026/06/05Shareholder Composition
Updated 2026/06/05Top Mutual Funds / ETFs
Updated 2026/06/05Major Holders
Updated 2026/06/05| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
9.3M | -10.75% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.6M | +0.47% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.3M | +1.51% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.6M | +2.13% | |
|
Tweedy, Browne Fund Inc.-TWEEDY, BROWNE INTERNATIONAL VALUE FUND
|
2.9M | +2.61% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
2.1M | +5.78% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
4.2K | -4.06% |
Dividend History
Updated 2026/06/14| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥19 | -47.2% |
| 2025 | ¥36 | +24.1% |
| 2024 | ¥29 | +3.6% |
| 2023 | ¥28 | +6.3% |
| 2022 | ¥26 | - |
Financial Performance
2026/06/14 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥363,780M | ¥410,502M | ¥461,510M | ¥508,643M |
| Gross Profit | ¥190,585M | ¥216,082M | ¥242,497M | ¥271,977M |
| Operating Income | ¥67,418M | ¥76,049M | ¥80,595M | ¥90,796M |
| Pretax Income | ¥65,255M | ¥70,279M | ¥76,986M | ¥82,739M |
| Net Income | ¥44,092M | ¥45,784M | ¥49,639M | ¥53,669M |
| EPS | ¥70.16 | ¥72.91 | ¥79.24 | - |
| Operating Margin | 18.53% | 18.53% | 17.46% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥483,707M | ¥531,074M | ¥618,920M | ¥665,268M |
| Total Equity | ¥348,303M | ¥387,665M | ¥432,045M | ¥463,776M |
| Total Liabilities | ¥135,404M | ¥143,409M | ¥186,875M | ¥201,492M |
| Cash | ¥73,752M | ¥69,460M | ¥75,507M | ¥89,570M |
| Interest-bearing Debt | ¥22,279M | ¥22,591M | ¥55,339M | ¥64,735M |
| Equity Ratio | 72.01% | 73.00% | 69.81% | 69.71% |
| D/E Ratio | 0.06 | 0.06 | 0.13 | 0.14 |
| Cash Flow | ||||
| Operating CF | ¥58,739M | ¥68,835M | ¥63,905M | ¥88,246M |
| Investing CF | -¥35,052M | -¥51,751M | -¥54,970M | -¥52,488M |
| Financing CF | -¥20,542M | -¥24,234M | -¥9,013M | -¥24,322M |
| Free CF | ¥26,705M | ¥26,330M | ¥13,714M | ¥38,287M |
| Efficiency | ||||
| ROE | 12.66% | 11.81% | 11.49% | 11.57% |
| ROA | 9.12% | 8.62% | 8.02% | 8.07% |
Latest IR Information
-
Notice Regarding Share Buyback
Sutissx Corporation announced that in May 2026, it purchased 5,592,800 shares of common stock through market purchases for 7,588,882,045 yen, and as of the end of May 2026, it had acquired a total of 13,465,700 shares.
Read more -
【Sysmex】2026 Fiscal Year Results｜Sales Decreased by 500 Billion Yen, Operating Profit of 5.1 Billion Yen
Sysmex's fiscal year ending March 2026 reported a decline in sales by 500 billion yen and an operating profit of 5.1 billion yen. Domestic sales declined by 13.5%, while overseas remained nearly flat. Net income decreased by 33.9%, and dividends...
Read more -
Notice Regarding Dividend Payment｜May 14, 2026
Sysmex has decided on a year-end dividend of 19 yen per share for the fiscal year ending March 2026, with an expected full-year dividend of 38 yen. The payout ratio is 67.3%, demonstrating a commitment to stable dividends and enhanced...
Read more -
[Sysmex] Completion of Share Buyback | April 2026
Sysmex acquired 6,177,600 shares of common stock through market purchase in April 2026, totaling 8,724,873,163 yen, thereby completing its share buyback.
Read more -
Notice Regarding Recognition of Impairment Loss (Consolidated Financial Statements) and Revision of Full-Year Earnings Forecast for Fiscal Year Ending March 2026
An impairment loss of 11,557 million yen was recorded for the fiscal year ending March 2026. Operating income has been revised down by 17.7% from the previous forecast to 51,000 million yen, and net income attributable to owners of parent...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥1,733
Rating Score: 2.27 (Based on 15 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
